Mink's agent-797 offers new hope in overcoming ici resistance in pd-1 refractory gastric cancer - published in oncogene

New york, jan. 30, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced the publication of a case report in oncogene from its phase 1/2 study in patients with advanced solid tumors where one infusion of agent-797 in gastric cancer refractory to anti-pd1 led to a durable confirmed partial response, highlighting the unique potential of inkt cells to overcome resistance to immune checkpoint inhibitors (icis).
INKT Ratings Summary
INKT Quant Ranking